Investigating Safety and Efficacy of L9LS Monoclonal Antibodies in Western Kenya

Program Description: To investigate other novel interventions, such as monoclonal antibodies (MAbs) against malaria. An intervention that could prevent malaria in children for a full 12 months in settings of perennial malaria transmission, such as Kenya, holds potential to reduce malaria morbidity and mortality substantially in this population at risk for severe malaria and death.
Funding Partners:
  • Bill & Melinda Gates Foundation
Program Partners:
  • CDC’s Center for Global Health
Program Location:
  • Kenya